YUROXAN
DEAD

Serial Number

77942356

Owner

MEDIGENE AG

Attorney

Adrienne L. White

Filing Date

Feb 23, 2010

Add to watchlist:

No watchlists yet
View on USPTO

YUROXAN Trademark

Serial Number: 77942356 • Registration: 4040189

YUROXAN is a trademark filed by MEDIGENE AG on February 23, 2010. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

MEDIGENE AG (25 trademarks)

Lochhamer Strasse 11
MARTINSRIED, MUNICH , DE

Entity Type: 03

Trademark Details

Filing Date

February 23, 2010

Registration Date

October 18, 2011

Published for Opposition

August 2, 2011

Cancellation Date

May 25, 2018

Goods & Services

Pharmaceutical and veterinary preparations for humans and animals, namely, medicines, vaccines, and serums for diagnostics, testing, prevention, treatment, and therapeutics, in particular medicines for treating cardiovascular illnesses, in particular hyperlipidaemia, coronary heart diseases and cardiac insufficiency; medicines for the treatment of immunological diseases, in particular autoimmune diseases in particular rheumatic disorders, polychondritis, Bechterew's disease, fibromyalgia and lupus erythematodes, rheumatoid arthritis, polyarthritis, Crohn's disease, and multiple sclerosis; medicines for treating skin diseases, in particular acne, actinic keratosis, alopecia, atopic dermatitis, Bowen's disease, cutaneous atopy, cutaneous T-cell lymphoma, Darrier's disease, Dartroud diathesis, dermatitis, eczema, genital herpes, genital warts, herpes, hyperkeratosis, hyperpigmentation, hyperplasia of the epidermis, hypopigmentation, ichthyosis, increased proliferation of skin cells, keloids, lentigo, lichen planus, melasma, molluscum contagiosum, mycosis fungoides, neoplasias, neurodermitis, pigmentation disorders, porokeratosis of Mibelli, psoriasis, removal of tattoos, rosacea, seborrhea, seborrheic keratosis, shingles, skin diseases related to inflammatory processes of skin cells, skin ulcers, vitiligo, warts, xerosis; medicines for treating tumourous diseases, in particular Astrocytomas, basal cell carcinomas, biliary cancers, bladder cancers, bone cancers, brain cancers, breast cancers, carcinomas, cervical cancers, cervical intraepithelial neoplasias, colorectal cancers, endocrine system cancers, ependymomas, epidermoid carcinomas, fibrosarcomas, gastric cancers, gastrointestinal cancers, glioblastomas, gynecologic cancers, head and neck cancers, hemangiomas, hepatomas, Hodgkin's lymphomas, Leukemia, liver cancers, lung cancers, lymphomas, medulloblastomas, meningiomas, mesothelaiomas, metastases, myelomas, neoplasias, neurectodermal cancers, neuroblastomas, neurofibromas, neurofibrosarcomas, neuronal cancers, non-Hodgkin's lymphomas, oligodendrogliomas, ovarian carcinoma, pancreatic cancers, pediatric cancers, penile cancer, pituitary adenomas, pleural cancers, renal cancer, sarcomas, Schwannomas, skin cancers, sqamous cell carcinomas, testicular cancers, thyroid cancers, thyroid tumors, urinary tract cancers, carcinoma of the prostate, melanoma, Kaposi's sarcoma, hepatocellular carcinoma; ALL OF THE ABOVE CONSISTING OF low-molecular active substances, liposomes, aptamers, nucleic acids, peptides, proteins, protein conjugates, antibodies, T-cell proteins, enzymes and enzyme preparations, hormones, hormone analogues, attenuated viruses, virus-type particles and plant extracts

Filing History

CANCELLED SEC. 8 (6-YR)
May 25, 2018 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 18, 2016 REM1
REGISTERED-PRINCIPAL REGISTER
Oct 18, 2011 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 2, 2011 NPUB
PUBLISHED FOR OPPOSITION
Aug 2, 2011 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 28, 2011 PREV
ASSIGNED TO LIE
Jun 24, 2011 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 22, 2011 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 22, 2011 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 22, 2011 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 22, 2011 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 22, 2011 CNEA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Jan 3, 2011 GPRN
PRIORITY ACTION E-MAILED
Jan 3, 2011 GPRA
PRIORITY ACTION WRITTEN
Jan 3, 2011 CPRA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 29, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 29, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 29, 2010 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
May 29, 2010 GPRN
PRIORITY ACTION E-MAILED
May 29, 2010 GPRA
PRIORITY ACTION WRITTEN
May 29, 2010 CPRA
ASSIGNED TO EXAMINER
May 27, 2010 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 1, 2010 NWOS
NEW APPLICATION ENTERED
Feb 26, 2010 NWAP